Foghorn Therapeutics (FHTX) Equity Average (2019 - 2026)

Foghorn Therapeutics' Equity Average history runs 8 years deep, the most recent figure standing at -$92.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 72.52% year-over-year to -$92.5 million; the TTM figure through Mar 2026 stood at -$92.5 million (down 72.52% YoY), while the FY2025 annual figure was -$77.0 million, down 25.51% from the prior year.
• Equity Average was -$92.5 million for Q1 2026 at Foghorn Therapeutics, up from -$99.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $84.6 million in Q1 2022 to a low of -$99.1 million in Q4 2025.
• Historically, Equity Average has averaged -$33.9 million across 5 years, with a median of -$53.4 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Average sank 650.76% in 2023, then jumped 60.08% in 2024.
• A 5-year view of Equity Average shows it stood at $12.2 million in 2022, then tumbled by 650.76% to -$67.3 million in 2023, then soared by 45.15% to -$36.9 million in 2024, then sank by 168.45% to -$99.1 million in 2025, then advanced by 6.69% to -$92.5 million in 2026.
• The last three Equity Average figures came in at -$92.5 million (Q1 2026), -$99.1 million (Q4 2025), and -$83.2 million (Q3 2025), per Business Quant data.